NCT04206787 2025-02-28The Study Observes Afatinib as First-line Treatment in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive Advanced Non-small Cell Lung CancerBoehringer IngelheimCompleted72 enrolled 12 charts
NCT04795245 2024-12-27Non-interventional Study for Real-world Data of Afatinib Treatment in First-line Setting and of Subsequent Therapies for Patients With Advanced Epidermal Growth Factor Receptor (EGFR) Mutation-positive Lung AdenocarcinomaBoehringer IngelheimCompleted805 enrolled 13 charts
NCT04750824 2024-09-19Real-World Effectiveness of Afatinib (Gilotrif) Following Immunotherapy in the Treatment of Metastatic, Squamous Cell Carcinoma of the Lung: A Multi-Site Retrospective Chart Review Study in the U.S.Boehringer IngelheimCompleted110 enrolled 24 charts
NCT02440854 2022-04-27Evaluate the Impact of Afatinib on Quality of Life and Symptom Burden of Greek Subjects With Advanced NSCLC in Routine Patient Care SettingsBoehringer IngelheimCompleted80 enrolled 37 charts
NCT04552535 2022-01-11A Study in the United States Using Electronic Medical Records (EMR) to Assess Effectiveness of Afatinib (Gilotrif) Following Pembrolizumab and Chemotherapy in the Treatment of Metastatic Squamous Cell Carcinoma of the LungBoehringer IngelheimCompleted200 enrolled 18 charts
NCT03370770 2020-12-24Afatinib Osimertinib Sequencing NISBoehringer IngelheimCompleted204 enrolled 10 charts
NCT02047903 2020-01-09GIOTRIF in First Line Therapy of Advanced NSCLC With EGFR-mutationsBoehringer IngelheimCompleted161 enrolled 15 charts
NCT02131259 2018-09-07Long-term Observation PMS for AfatinibBoehringer IngelheimCompleted1,605 enrolled 7 charts